TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial evaluating TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurrence risk in a high-risk population.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. The study is being conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, and will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
The trial focuses on patients with minimal residual disease (MRD), a condition where cancer cells persist at levels undetectable by standard imaging but identifiable through liquid biopsy. These patients face a significantly elevated risk of recurrence, making them a critical target for therapeutic intervention. TTX-MC138 is designed to target metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. By addressing MRD early, the therapy aims to prevent or delay disease progression.
“The initiation of this Phase 2a trial marks a significant step forward in our clinical development program,” said a company spokesperson. “We believe TTX-MC138 has the potential to improve outcomes for colorectal cancer patients with minimal residual disease, a population with high unmet medical need.”
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The announcement underscores the growing importance of liquid biopsy in oncology, enabling earlier detection of residual disease and personalized treatment strategies. For more details on the trial, the full press release is available at https://ibn.fm/wuRri. Investors can find the latest news and updates on RNAZ in the company’s newsroom at https://ibn.fm/RNAZ.